April 8, 2010 (FinancialWire) — ICON (NASDAQ: ICLR) (ISIN: IE0005711209), a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and Tigermed Consulting, a provider of clinical drug development services in China, said they have signed an alliance agreement.

Through this agreement, ICON and Tigermed said they will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilising the global reach and experience of the ICON organisation, complemented by Tigermed’s knowledge of the Chinese drug development landscape and geographic coverage in China.

Tigermed currently operates from 21 offices in China and has over 300 clinical development staff located there.

Ireland-based ICON provides outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

(For more biomedical, biotech and/or pharmaceutical related articles go to http://www.financialwire.net/?s=biomedphrm) (For more Chinese company related articles go to http://www.financialwire.net/?s=chnchn)

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.